Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.

Breast cancer research and treatment - 1 Nov 2003

Sensi Elisa, Tancredi Mariella, Aretini Paolo, Cipollini Giovanna, Naccarato A Giuseppe, Viacava Paolo, Bevilacqua Generoso, Caligo Maria A

Abstract excerpt

Germline mutations at BRCA1 or BRCA2 genes result in susceptibility to breast and ovarian cancers. BRCA1- and BRCA2-associated tumors have distinct histologic and molecular phenotypes, as compared to sporadic breast tumors. Typically, a higher grade of malignancy is observed in BRCA-associated cancers. A number of studies have suggested that BRCA1 and BRCA2 proteins are of importance in DNA repair and maintenance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms, Male
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Genes, p53

Share to Germ-Line Mutation

Share to Point Mutation

Share to Polymorphism, Single-Stranded Conformational

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 14672397
DOI: 10.1023/B:BREA.0000003836.91844.b5

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.PMID 14672397Read ↗

The Brca1 and Brca2 proteins and tumor pathogenesis.Semantic proximity Read ↗

Is TP53 dysfunction required for BRCA1-associated carcinogenesis?Semantic proximity Read ↗

Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.Semantic proximity Read ↗

Non-BRCA familial breast cancer: review of reported pathology and molecular findings.Semantic proximity Read ↗

p53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer.Semantic proximity Read ↗

The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in <i>BRCA1</i> and <i>BRCA2</i>Semantic proximity Read ↗

Histopathology of BRCA1- and BRCA2-associated breast cancer.Semantic proximity Read ↗

Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.Semantic proximity Read ↗

Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours.Semantic proximity Read ↗

Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.Semantic proximity Read ↗

p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.Semantic proximity Read ↗

TP53Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.